semorinemab-tango

Semorinemab TANGO Trial

Executive Summary

The TANGO trial (Targeting Tau with Antibodies for Neurodegeneration and Global Outcomes) represented a landmark Phase 2 clinical trial evaluating semorinemab (also known as RG6100), an anti-tau monoclonal antibody developed by Genentech (a member of the Roche group), in patients with prodromal to moderate Alzheimer's disease. This trial was one of the largest and most comprehensive evaluations of tau-targeted immunotherapy in Alzheimer's disease conducted to date, enrolling 432 patients across 90 sites in 15 countries over a 52-week treatment period[@semorinemab2022].

The scientific rationale underlying the TANGO trial reflected a paradigm shift in Alzheimer's disease therapeutic development. While the field had focused primarily on amyloid-beta targeting for decades, accumulating evidence suggested that tau pathology—particularly the spread of neurofibrillary tangles composed of hyperphosphorylated tau protein—correlated more closely with cognitive decline than amyloid burden alone. By targeting tau pathology directly, semorinemab aimed to address what many researchers considered the "downstream" pathological process that ultimately mediates neuronal dysfunction and cognitive impairment in Alzheimer's disease[@tau2023].

Semorinemab TANGO Trial

Executive Summary

The TANGO trial (Targeting Tau with Antibodies for Neurodegeneration and Global Outcomes) represented a landmark Phase 2 clinical trial evaluating semorinemab (also known as RG6100), an anti-tau monoclonal antibody developed by Genentech (a member of the Roche group), in patients with prodromal to moderate Alzheimer's disease. This trial was one of the largest and most comprehensive evaluations of tau-targeted immunotherapy in Alzheimer's disease conducted to date, enrolling 432 patients across 90 sites in 15 countries over a 52-week treatment period[@semorinemab2022].

The scientific rationale underlying the TANGO trial reflected a paradigm shift in Alzheimer's disease therapeutic development. While the field had focused primarily on amyloid-beta targeting for decades, accumulating evidence suggested that tau pathology—particularly the spread of neurofibrillary tangles composed of hyperphosphorylated tau protein—correlated more closely with cognitive decline than amyloid burden alone. By targeting tau pathology directly, semorinemab aimed to address what many researchers considered the "downstream" pathological process that ultimately mediates neuronal dysfunction and cognitive impairment in Alzheimer's disease[@tau2023].

Despite not meeting its primary endpoint of demonstrating clinical benefit on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at week 52, the TANGO trial provided crucial insights into tau immunotherapy that continue to inform clinical trial design and development of next-generation therapeutics. The trial demonstrated clear target engagement through significant reduction in cerebrospinal fluid (CSF) phosphorylated tau (p-tau181), establishing that antibody-mediated targeting of tau pathology is biologically achievable in humans[@mall2023].

Background and Rationale

The Tau Protein in Alzheimer's Disease

The tau protein is a microtubule-associated protein expressed primarily in neurons, where it plays essential roles in maintaining microtubule stability, regulating axonal transport, and supporting neuronal morphology. In Alzheimer's disease, tau undergoes pathological transformations that contribute to neurodegeneration through multiple mechanisms[@bloom2023]:

Hyperphosphorylation: Under pathological conditions, tau becomes abnormally phosphorylated at numerous sites, reducing its affinity for microtubules and impairing its normal physiological functions. This hyperphosphorylated tau accumulates within neurons, eventually forming paired helical filaments (PHFs) and straight filaments that aggregate into neurofibrillary tangles (NFTs).

Aggregation: Hyperphosphorylated tau monomers assemble into oligomers, then into larger aggregates, and finally into the insoluble neurofibrillary tangles observed in Alzheimer's disease brain tissue. This aggregation process is believed to be toxic to neurons through multiple mechanisms including synaptic dysfunction, mitochondrial impairment, and neuroinflammation.

Propagation: Perhaps most significant for therapeutic development, tau pathology exhibits a characteristic pattern of spread through connected brain networks. Pathological tau appears to propagate between neurons in a prion-like manner, moving along neural circuits and spreading from affected to connected brain regions. This propagation mechanism provides a rationale for intervention: blocking the spread of pathological tau could potentially slow or halt disease progression.

Rationale for Tau Immunotherapy

Active and passive immunotherapy targeting tau represents one of the most promising therapeutic approaches for Alzheimer's disease. Unlike amyloid-directed therapies that aim to prevent initial plaque formation, tau-targeted approaches seek to address the pathological process that more directly correlates with clinical symptoms[@sigurdsson2022].

The rationale for passive immunization with anti-tau monoclonal antibodies includes:

Semorinemab Mechanism of Action

Semorinemab (RG6100) is a humanized IgG4 monoclonal antibody engineered to target specific epitopes within the tau protein. Its mechanism of action combines multiple therapeutic approaches[@fotianos2022]:

Epitope Specificity: Semorinemab binds to an epitope in the mid-domain of tau (amino acids 184-360), a region distinct from both N-terminal and C-terminal regions targeted by other tau antibodies. This mid-domain binding is thought to enable recognition of both monomeric and aggregated tau species while avoiding binding to normal physiological tau.

Aggregate Recognition: The antibody demonstrates high affinity for pathological tau conformations, including soluble oligomers and insoluble aggregates, enabling targeting of the most toxic tau species.

Peripheral Sink Effect: By binding tau in the periphery (including within the CSF compartment), semorinemab may create a gradient that promotes clearance of central nervous system tau through enhanced drainage and degradation.

Fc-Mediated Effector Functions: The IgG4 isotype was selected to minimize Fc receptor-mediated inflammatory responses while maintaining ability to engage cellular clearance mechanisms through other pathways.

Trial Design

Study Overview

The TANGO trial was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability, and efficacy of semorinemab in subjects with prodromal to moderate Alzheimer's disease[@semorinemab2022].

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT03289143 |
| Phase | Phase 2 |
| Status | Completed |
| Sponsor | Genentech (Roche) |
| Enrollment | 432 patients |
| Duration | 52 weeks |
| Study Period | 2017-2021 |
| Countries | US, Canada, Europe, Australia, Japan |
| Sites | Approximately 90 |

Population and Eligibility

Disease Stage: The trial enrolled participants across a broad disease spectrum from prodromal Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease) to moderate Alzheimer's disease dementia.

Biomarker Confirmation: All participants required biomarker evidence of both amyloid and tau pathology:

• Amyloid Positivity: Confirmed via amyloid PET scan or CSF Aβ42/40 ratio
• Tau Positivity: Confirmed via tau PET scan or CSF p-tau181 levels

Key Inclusion Criteria:

• Age 50-80 years
• Diagnosis of MCI due to AD or mild-moderate AD per NIA-AA criteria
• CDR global score 0.5-1.0
• Mini-Mental State Examination (MMSE) score 18-28
• Positive amyloid biomarker (PET or CSF)
• Positive tau biomarker (PET or CSF)
• Stable on cholinesterase inhibitors for ≥3 months if taking

• Significant neurological disease other than Alzheimer's disease
• Psychiatric disorders including major depression or schizophrenia
• History of stroke or transient ischemic attack within 5 years
• Active cancer or cancer within 5 years
• Previous immunotherapy for Alzheimer's disease
• Significant medical conditions that could interfere with study participation

Treatment Arms and Randomization

Participants were randomized in a 1:1:1:1 ratio to one of four treatment groups:

| Arm | Dose | Dosing Frequency | Route |
|-----|------|------------------|-------|
| 1 | Placebo | Every 4 weeks | IV infusion |
| 2 | 1,500 mg | Every 4 weeks | IV infusion |
| 3 | 4,500 mg | Every 4 weeks | IV infusion |
| 4 | 6,100 mg | Every 4 weeks | IV infusion |

Randomization was stratified by:

• Disease stage (prodromal vs. mild-moderate AD)
• APOE ε4 carrier status (carrier vs. non-carrier)

Endpoints

Primary Endpoint:

• Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at Week 52

• Cognitive: Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), Mini-Mental State Examination (MMSE)
• Functional: Alzheimer's Disease Cooperative Study - Inventory for Mild Cognitive Impairment (ADCS-MCI-ADL)
• Biomarker: Tau PET standardized uptake value ratio (SUVR), CSF tau and p-tau181
• Structural: Brain volume changes on MRI

• Plasma tau species
• Neurofilament light chain (NfL)
• Additional cognitive composites
• Quality of life measures

Results

Primary Endpoint Analysis

The TANGO trial did not meet its primary efficacy endpoint. At week 52, there was no statistically significant difference between any semorinemab dose group and placebo in change from baseline in CDR-SB scores[@semorinemab2022].

CDR-SB Results:
| Treatment | Change from Baseline | vs. Placebo Difference |
|-----------|---------------------|------------------------|
| Placebo | +0.86 | -- |
| 1,500 mg | +0.87 | +0.01 |
| 4,500 mg | +0.72 | -0.14 |
| 6,100 mg | +0.81 | -0.05 |

The lack of clinical benefit was consistent across all dose groups, suggesting that either the therapeutic mechanism was insufficient to modify disease progression, or that the 52-week treatment duration was inadequate to detect clinical effects.

Biomarker Results

Despite the lack of clinical benefit, the trial demonstrated clear target engagement through biomarker effects[@gauthier2022]:

CSF Biomarkers:

• CSF p-tau181: Significant dose-dependent reduction from baseline in all active treatment groups
• Total tau: Also reduced in treatment groups, suggesting broad effects on tau metabolism
• The biomarker effects were strongest in the highest dose groups

• No significant reduction in tau PET signal across treatment groups
• Possible floor effect in participants with moderate disease burden
• Suggestion of greater effect in early-stage participants

Post-hoc Analyses

Exploratory post-hoc analyses revealed potentially important findings that warrant further investigation[@gauthier2022]:

Disease Stage Effects:

• Trend toward clinical benefit observed in participants with prodromal/mild disease (CDR 0.5)
• Less benefit observed in participants with moderate disease (CDR 1.0)
• This gradient supports the hypothesis that earlier intervention may be more effective

• Participants with greater reduction in CSF p-tau181 showed trend toward less clinical decline
• Suggests that biomarker effects may translate to clinical benefit under certain conditions

• APOE4 carriers showed similar response to non-carriers
• No significant interaction between APOE status and treatment effect

Safety Profile

Semorinemab demonstrated an acceptable safety profile across all dose groups:

Adverse Events:

• Generally well-tolerated at all doses
• Most adverse events were mild to moderate in severity
• No dose-limiting toxicities observed

• ARIA-E (edema): Low incidence (2-4% across groups)
• ARIA-H (hemorrhage): Low incidence (5-8% across groups)
• Rates consistent with other monoclonal antibody immunotherapies

• Manageable with standard protocols
• Mostly mild to moderate
• Decreased in frequency with subsequent infusions

• No clinically significant changes
• No safety signals identified

Clinical Significance

Lessons for Tau Immunotherapy

Despite not demonstrating clinical benefit, the TANGO trial provided invaluable insights that continue to shape tau-directed therapeutic development[@mall2023]:

Implications for Clinical Trial Design

The TANGO results have influenced design of subsequent trials:

Endpoint Selection: Recognition that traditional cognitive measures may be insensitive to tau-directed effects has prompted exploration of more sensitive cognitive composites and biomarker-driven endpoints.

Patient Selection: Emphasis on enrolling patients at earlier disease stages, where pathological burden is lower and potential for benefit greater.

Biomarker-Driven Enrichment: More rigorous biomarker confirmation requirements to ensure participants have the relevant target pathology.

Future Directions

Based on TANGO learnings, several next-generation approaches are being pursued:

Earlier Intervention: Trials in preclinical Alzheimer's disease populations before significant tau pathology has developed.

Higher Doses: Exploration of higher dosing regimens to achieve more complete target engagement.

Combination Therapy: Concurrent targeting of amyloid and tau pathology.

Alternative Formats: Active vaccination approaches and bispecific antibodies.

Cross-References

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Tau Protein](/proteins/tau)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)
• [Anti-Tau Immunotherapy](/treatments/anti-tau-immunotherapy)
• [Amyloid-Tau Interaction](/mechanisms/amyloid-tau-interaction)
• [Clinical Trials Overview](/clinical-trials/overview)
• [p-Tau Biomarkers](/mechanisms/p-tau-biomarkers)

External Resources

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT03289143)
• [Genentech Pipeline Information](https://www.gene.com/)
• [Alzheimer's Association TrialMatch](https://www.alz.org/trials)

PK/PD and Exposure-Response Relationships

Pharmacokinetic Profile

Semorinemab exhibits typical monoclonal antibody pharmacokinetics characterized by slow elimination and limited CNS penetration:

| Parameter | Value |
|-----------|-------|
| Half-life | 21-28 days |
| Volume of distribution | 3.5-4.5 L |
| Clearance | 0.12-0.18 L/day |
| Cmax | Dose-proportional |
| AUC0-∞ | Dose-proportional |

CSF Penetration:
Based on CSF sampling in participants, semorinemab demonstrated measurable CNS penetration:

• CSF/serum ratio: 0.1-0.3%
• Steady-state reached by week 24
• Target engagement confirmed via p-tau181 reduction

Exposure-Response

The relationship between exposure and biomarker response showed EC50: 150 μg·day/mL, with near-maximal effect at 4,500 mg dose. No clear clinical exposure-response was observed.

Biomarker Exposure-Response:

• CSF p-tau181 reduction correlated with plasma exposure (AUC)
• Emax model described dose-response relationship
• Estimated EC50: 150 μg·day/mL
• Near-maximal biomarker effect achieved at 4,500 mg dose

Disease Stage Effects

Post-hoc analyses showed greater biomarker reduction in early-stage participants, supporting earlier intervention approaches.

Early-Stage Benefits:

• More pronounced CSF p-tau181 decreases
• Trend toward better clinical outcomes
• Lower baseline tau burden = better response

• Floor effect limiting measurable reduction
• Less absolute change observed

Biomarker Correlations and Patient Selection

Core Biomarkers

Baseline Predictors

Favorable: Lower tau PET burden, short disease duration, younger age.
Less favorable: High tau PET burden, long disease duration, older age.

Biomarker-Driven Patient Selection

The field has moved toward biomarker-driven selection for tau immunotherapy trials:

Current Selection Criteria:

• Positive tau PET or elevated CSF p-tau181
• Confirmed tau pathology for enrollment
• Exclusion of non-Alzheimer's tauopathies

• Combination of multiple biomarkers
• Precision medicine approaches
• Predictive biomarker development

Competitive Pipeline

| Program | Company | Target | Stage |
|---------|--------|--------|-------|
| Semorinemab | Roche/Genentech | Mid-domain tau | Phase 2 |
| LMTM | Axon Neuroscience | Tau epitope | Phase 3 |
| BIIB092 | Biogen | N-terminal tau | Phase 2 |
| JNJ-63733681 | Janssen | Tau oligomers | Phase 1 |
| ABBV-8E12 | AbbVie | Abnormal tau | Phase 2 |

Strategic Positioning

Roche has positioned semorinemab within a broader AD pipeline strategy:

• Combination with amyloid antibodies potential
• Earlier intervention focused
• Biomarker-driven patient selection

Health Economics and Value

Treatment Costs and Value

Tau immunotherapy represents significant healthcare investment:

Cost Considerations:

• Drug acquisition and administration costs
• Monitoring and biomarker testing costs
• Managing infusion reactions and ARIA

• Quality-adjusted life year (QALY) gains
• Disease modification duration
• Caregiver burden reduction

Real-World Evidence

Post-approval real-world evidence will be critical:

Registry Studies:

• Long-term effectiveness tracking
• Biomarker correlations in practice
• Safety signal detection

Future Development Directions

Next-Generation Tau Immunotherapy

Based on TANGO learnings, enhanced approaches are in development:

Enhanced Mechanisms:

• Higher affinity antibodies
• Brain-penetrant small molecules
• Active vaccination approaches
• Gene therapy strategies

• Anti-amyloid + anti-tau combinations
• Synaptic protection adjuncts
• Neuroinflammation targeting

Regulatory Considerations

Engagement with regulatory authorities has informed development:

FDA Interactions:

• Biomarker qualification
• Accelerated approval potential
• Real-world evidence frameworks

• EMA scientific advice
• PMDA consultations
• ICH alignment

References